DOCSLIB.ORG

Summary of Product Characteristics, Labelling and Package Leaflet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summary of Product Characteristics, Labelling and Package Leaflet SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET Page 1 of 26 SUMMARY OF PRODUCT CHARACTERISTICS Page 2 of 26 1. NAME OF THE MEDICINAL PRODUCT Betaxolol Hydrochloride 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 20 mg betaxolol hydrochloride (equivalent to 17.88 mg betaxolol). Excipient with known effect Each film-coated tablet contains 100.00 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet White, round, biconvex film-coated tablets with a break-line on one face. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Betaxolol Hydrochloride is indicated in adults for: Treatment of essential hypertension. Chronic, stable angina pectoris. 4.2 Posology and method of administration Posology Adults Essential hypertension The initial dose is 10 mg once daily. In case of insufficient effect this dosage can be increased to 20 mg per day. In moderate hypertension the standard dose is 20 mg once daily. In certain cases it could be necessary to increase the daily dose to 40 mg. Stable angina pectoris The dosage should be adjusted individually. The starting dose is 10 mg a day, which can be increased to the usual dose of 20 mg once daily. In certain cases it could be necessary to increase the daily dose to 40 mg. Patients with impaired renal or liver function In patients with renal impairment (creatinine clearance up to 20 ml/minute) there is no need to adjust the daily dose, however, clinical monitoring at the beginning of the treatment until steady plasma levels of the medicinal product are attained (over 4 days on average) is recommended. Page 3 of 26 In patients with severe renal impairment (creatinine clearance below 20 ml/minute) and in patients with haemo- or peritoneal dialysis the dose of 10 mg/day should not be exceeded. In patients on dialysis the daily dose can be given independent of the time of dialysis. In patients with liver failure there is no need to adjust the dose. Careful clinical monitoring is recommended at the beginning of the treatment. Elderly patients The treatment of elderly patients should be started cautiously with low doses and under close monitoring (see section 4.4). Paediatric population The safety and efficacy of betaxolol in children has not yet been established. Betaxolol hydrochloride should not be used in children (see section 4.4). Method of administration Oral use. Betaxolol Hydrochloride should always be taken at the same time of the day, preferably in the early morning. The tablets may be taken with or without food. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 Severe forms of bronchial asthma and chronic obstructive pulmonary disease Decompensated heart failure Cardiogenic shock Second and third degree atrioventricular block, unless a pacemaker is inserted Prinzmetal's variant angina pectoris (pure form and with monotherapy) Sick-sinus syndrome, including sinoatrial block Bradycardia (less than 45-50 beats/min) Severe forms of Raynaud's phenomenon and peripheral arterial disorders Untreated pheochromocytoma Hypotension History of anaphylactic reaction Metabolic acidosis Concurrent administration with floctafenine or sultopride (see section 4.5) 4.4 Special warnings and precautions for use The treatment must not be discontinued suddenly in patients with stable angina pectoris: this could result in serious heart rhythm disorders, myocardial infarction or sudden death. Discontinuation of treatment The treatment should not be discontinued suddenly, especially in patients with ischaemic heart disease. The doses should be reduced gradually, within a one to two-week period. If necessary, with simultaneous introduction of replacement therapy to prevent any aggravation of angina pectoris. Asthma and chronic obstructive lung disease Beta-blockers may be administered only in mild forms of the disease, cardio selective beta-blockers at the lowest possible doses should be preferably used and it is recommended to carry out pulmonary function tests before and after the start of beta-blocker treatment. During an asthma attack beta2-agonist bronchodilators may be used. Page 4 of 26 Heart failure In patients with compensated heart failure, betaxolol can be administered in gradually increasing doses, if necessary. At the start of treatment very low doses should be administered. Close monitoring of the patient's condition is required. Bradycardia Beta-blockers may induce bradycardia. The dosage of betaxolol hydrochloride must be decreased, if the resting heart rate of the patient drops below 50-55 beats per minute and symptoms of bradycardia appear. First degree atrioventricular block With respect to the negative dromotropic effect of beta-blockers, betaxolol should be administered with caution to patients with first-degree atrioventricular block. Prinzmetal variant of angina Beta-blockers may increase the number and duration of angina attacks in patients suffering from the Prinzmetal’s variant angina pectoris (see section 4.3). Cardioselective beta-blockers may be used in minor and mixed forms, provided that a vasodilator is co-administered. Peripheral arterial disorders In patients with peripheral arterial disorders (Raynaud's syndrome or disease, arteritis, or chronic occlusive arterial disease of the lower limbs), beta-blockers should be used with great caution as they may result in an aggravation of the condition. In severe forms of Raynaud’s phenomenon and peripheral arterial circulatory disorders, beta-blockers are contraindicated (see section 4.3). Pheochromocytoma The use of beta-blockers in the treatment of hypertension caused by treated pheochromocytoma requires close monitoring of the patient's blood pressure (see section 4.3).Beta blockers should only be used after prior administration if alpha inhibitors Paediatric population The safety and efficacy of betaxolol has not yet been established, therefore betaxolol is not recommended in children and adolescents. Elderly patients In elderly patients, the treatment should be initiated at low doses and the patient´s clinical condition must be closely monitored (see section 4.2). Patients with renal impairment In patients with renal impairment, the dosage should be adjusted according to the serum creatinine levels or creatinine clearance (see section 4.2). Diabetic patients Beta-blockers may mask some signs of hypoglycaemia, particularly tachycardia, palpitations and sweats (see section 4.5 and 4.8). The patient must be informed about the necessity of blood glucose monitoring at shorter intervals, in particular at the start of treatment. Psoriasis The benefit of beta-blockers in patients with a personal or family history of psoriasis should be carefully weighed, as it has been reported that psoriasis has been aggravated in patients treated with beta-blockers (see section 4.8). Page 5 of 26 Allergic reactions In patients liable to have a severe anaphylactic reaction, irrespective of its cause, especially after the administration of iodine-containing contrast media or floctafenine (see sections 4.3 and 4.5) or during desensitising therapy, beta-blocker treatment may result in an aggravated allergic reaction and resistance to treatment by the usual doses of adrenaline. General anaesthesia Beta-blockers attenuate reflex tachycardia and increase the risk of hypotension. Continuation of beta- blocker therapy reduces the risk of arrhythmias, myocardial ischemia and hypertensive crisis. Anaesthetists should be informed that the patient is being treated with a beta-blocker. Anaesthetics with the least possible myocardial depressant effects should be used. It is necessary to take into account the probability of anaphylaxis. If discontinuation of the treatment is necessary, a 48-hour period is considered sufficient to restore the normal sensitivity to the catecholamines. In some cases, beta-blocker therapy should not be interrupted: in patients with coronary insufficiency, due to a risk associated with an abrupt beta-blocker withdrawal, it is advisable to continue the treatment until the surgery in emergency or in cases when discontinuation is impossible, the patient must be protected from parasympathetic predominance by a sufficient premedication with atropine, repeated as needed Ophthalmology Beta-adrenergic blockade reduces intraocular pressure and may hamper the glaucoma screening. The ophthalmologist should be informed that the patient is being treated with betaxolol. Patients with general and ocular beta-blocker therapy should be monitored due to a potential additive effect. Thyrotoxicosis Beta-blockers can mask the cardiovascular signs of thyrotoxicosis. Hypoglycaemia There is an increased susceptibility to hypoglycaemia, for example during prolonged fasting or heavy physical exertion. Excipients Betaxolol hydrochloride contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 4.5 Interaction with other medicinal products and other forms of interaction Contraindicated combinations Floctafenine In the event of shock or hypotension caused by floctafenine, beta-blockers reduce the compensation reaction. Sultopride Disorders of cardiac automatism (excessive bradycardia) due to their common bradycardic effect. Not recommended combinations Page 6 of 26 Amiodarone Concomitant
Load more

Recommended publications
  • The Effect of Topical Beta-Adrenoceptor Blocking Agents on Pulsatile Ocular Blood Flow
    THE EFFECT OF TOPICAL BETA-ADRENOCEPTOR BLOCKING AGENTS ON PULSATILE OCULAR BLOOD FLOW C. D. MORSMAN, M. E. BOSEM, M. LUSKY and R. N. WEINREB San Diego, California SUMMARY factors (e.g. hypertension, diabetes, peripheral Thirty-three ocular hypertensive patients (21 with vascular disease and vasospasm) to the vascular primary open angle glaucoma and 12 glaucoma system suggest that blood flow in the optic nerve suspects) were randomly assigned to receive either head and retina may be altered in glaucoma.4 Of the timolol, levobunolol or betaxolol in one eye. Pulsatile various vascular beds within the posterior segment, ocular blood flow (POBF) was measured before the choroidal circulation is of particular interest since treatment (baseline) and 2 hours after drop adminis­ it provides the major contribution to the blood flow tration. After 1 week of regular twice-daily dosage, of the optic nerve at the level of the lamina cribrosa.5 POBF was measured again both immediately before Beta-2 adrenergic receptors have been demon­ and 2 hours after drop instillation. All measurements strated in human optic nerve,6 as well as in choroidal were made by an investigator masked to treatment. and retinal blood vessels.7 Blockade of these POBF increased by 11% (p = 0.09) at week 0 after receptors can cause vasoconstrictionS which could levobunolol administration, and by 22% (p = 0.20) at adversely affect visual function if adequate concen­ week 1 before drop administration compared with trations of the drug diffused into the posterior baseline. It dropped by 23% and 25% (p = 0.04 and segment of the eye or were absorbed systemically.
    [Show full text]
  • Use of Emulsions for Intra- and Periocular Injection
    (19) & (11) EP 1 611 879 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/107 (2006.01) 12.08.2009 Bulletin 2009/33 (21) Application number: 04291684.1 (22) Date of filing: 02.07.2004 (54) Use of emulsions for intra- and periocular injection Verwendung von Emulsionen zur intra- und periocularen Injection Utilisation des émulsions pour injection intra- et périoculaire. (84) Designated Contracting States: (74) Representative: de Mareüil-Villette, Caroline et al AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cabinet Plasseraud HU IE IT LI LU MC NL PL PT RO SE SI SK TR 52 rue de la Victoire 75440 Paris Cedex 09 (FR) (43) Date of publication of application: 04.01.2006 Bulletin 2006/01 (56) References cited: EP-A- 0 521 799 EP-A- 1 020 194 (73) Proprietors: WO-A-02/09667 WO-A-93/18852 • Novagali Pharma S.A. WO-A-94/05298 WO-A-03/053405 91000 Evry (FR) US-A- 5 632 984 • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) • KLANG S H ET AL: "PHYSICOCHEMICAL 75016 Paris (FR) CHARACTERIAZATION AND ACUTE TOXICITY • INSTITUT NATIONAL DE LA SANTE ET DE LA EVALUATION OF A POSITIVELY-CHARGED RECHERCHE MEDICALE (INSERM) SUBMICRON EMULSION VEHICLE" JOURNAL 75013 Paris (FR) OF PHARMACY AND PHARMACOLOGY, • YISSUM RESEARCH DEVELOPMENT COMPANY LONDON, GB, vol. 46, no. 12, December 1994 OF THE HEBREW UNIVERSITY OF JERUSALEM (1994-12), pages 986-993, XP008005426 ISSN: 91390 Jerusalem (IL) 0022-3573 • KLANG S ET AL: "INFLUENCE OF EMULSION (72) Inventors: DROPLET SURFACE CHARGE ON • Rabinovich-Guilatt, Laura INDOMETHACIN OCULAR TISSUE 75015 Paris (FR) DISTRIBUTION" PHARMACEUTICAL • De Kozak, Yvonne DEVELOPMENT AND TECHNOLOGY, NEW 75013 Paris (FR) YORK, NY, US, vol.
    [Show full text]
  • Guidance for the Format and Content of the Protocol of Non-Interventional
    PASS information Title Metformin use in renal impairment Protocol version identifier Version 2 Date of last version of 30 October 2013 protocol EU PAS register number Study not registered Active substance A10BA02 metformin Medicinal product Metformin Product reference N/A Procedure number N/A Marketing authorisation 1A Farma, Actavis, Aurobindo, Biochemie, Bluefish, holder(s) Hexal, Mylan, Orifarm, Pfizer, Sandoz, Stada, Teva Joint PASS No Research question and To assess the use and safety of metformin in patients objectives with and without renal insufficiency in current clinical practice in at least two EU Member States. Country(-ies) of study Denmark, United Kingdom Author Christian Fynbo Christiansen, MD, PhD Page 1/214 Marketing authorisation holder(s) Marketing authorisation N/A holder(s) MAH contact person N/A Page 2/214 1. Table of Contents PASS information .......................................................................................................... 1 Marketing authorisation holder(s) .................................................................................... 2 1. Table of Contents ...................................................................................................... 3 2. List of abbreviations ................................................................................................... 4 3. Responsible parties .................................................................................................... 5 4. Abstract ..................................................................................................................
    [Show full text]
  • Canine Red Eye Elizabeth Barfield Laminack, DVM; Kathern Myrna, DVM, MS; and Phillip Anthony Moore, DVM, Diplomate ACVO
    PEER REVIEWED Clinical Approach to the CANINE RED EYE Elizabeth Barfield Laminack, DVM; Kathern Myrna, DVM, MS; and Phillip Anthony Moore, DVM, Diplomate ACVO he acute red eye is a common clinical challenge for tion of the deep episcleral vessels, and is characterized general practitioners. Redness is the hallmark of by straight and immobile episcleral vessels, which run Tocular inflammation; it is a nonspecific sign related 90° to the limbus. Episcleral injection is an external to a number of underlying diseases and degree of redness sign of intraocular disease, such as anterior uveitis and may not reflect the severity of the ocular problem. glaucoma (Figures 3 and 4). Occasionally, episcleral Proper evaluation of the red eye depends on effective injection may occur in diseases of the sclera, such as and efficient diagnosis of the underlying ocular disease in episcleritis or scleritis.1 order to save the eye’s vision and the eye itself.1,2 • Corneal Neovascularization » Superficial: Long, branching corneal vessels; may be SOURCE OF REDNESS seen with superficial ulcerative (Figure 5) or nonul- The conjunctiva has small, fine, tortuous and movable vessels cerative keratitis (Figure 6) that help distinguish conjunctival inflammation from deeper » Focal deep: Straight, nonbranching corneal vessels; inflammation (see Ocular Redness algorithm, page 16). indicates a deep corneal keratitis • Conjunctival hyperemia presents with redness and » 360° deep: Corneal vessels in a 360° pattern around congestion of the conjunctival blood vessels, making the limbus; should arouse concern that glaucoma or them appear more prominent, and is associated with uveitis (Figure 4) is present1,2 extraocular disease, such as conjunctivitis (Figure 1).
    [Show full text]
  • Antiglaucoma Compositions Containing Combinations of Alpha-2 Agonists and Beta-Blockers
    ~" ' MM II II II MM II II II Ml II II I II J European Patent Office _ _ _ © Publication number: 0 365 662 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 09.03.94 © Int. CI.5: A61 K 31/47 © Application number: 89905874.7 @ Date of filing: 26.04.89 © International application number: PCT/US89/01994 © International publication number: WO 89/10126 (02.11.89 89/26) (54) ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS. ® Priority: 26.04.88 US 186504 1075-1078 @ Date of publication of application: J. of Cardiovascular Pharmacology, vol. 2, 02.05.90 Bulletin 90/18 suppl. 1, 1980, S. 21-28 © Publication of the grant of the patent: © Proprietor: ALCON LABORATORIES INC 09.03.94 Bulletin 94/10 6201 South Freeway Ft. Worth, TX 76134(US) © Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE @ Inventor: DE SANTIS, Louis, M. 2316 Wlnton Terrace West © References cited: Fort Worth, TX 761 09(US) US-A- 4 455 317 US-A- 4 515 800 © Representative: Jump, Timothy John Simon et AM A DRUG EVALUATION, 2nd ed., 1973; al "Agent used to treat Glaucoma", pp. 675-686. Venner Shipley & Co. 20 Little Britain GLAUCOMA, vol. 1, no. 1, February 1979; London EC1A 7DH (GB) 00 S.SUGAR, pp. 9-15. CM CO Ophthalmology, vol. 96, no. 1, 1989, p. 3-7 CO m Ophthalmology, vol. 98, no. 7, 1991, p. CO 00 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Glaucoma Medical Treatment: Philosophy, Principles and Practice
    Glaucoma medical CLIVE MIGDAL treatment: philosophy, principles and practice Abstract assessment of these parameters. Indeed There have been numerous recent advances in compounds are under evaluation that affect the the management of glaucoma, not least the function of the optic nerve (via improved blood development of new drugs to help manage supply or improved neuronal cell physiology) raised intraocular pressure. In addition, the but may or may not lower lOP. It may even be concepts of improving blood flow to the optic possible in the future to therapeutically alter the nerve head and neuroprotection are currently human genome, genetically deliver provoking considerable interest. This article neuroprotective substances or aid regeneration considers the aims and philosophy of of the optic nerve axons. glaucoma drug therapy, summarises some of The main aim of glaucoma therapy must still the basic facts and principles of modem be the preservation of visual function. At the glaucoma medications, and suggests a same time, the therapy should not have adverse practical approach to the choice of therapy. side effects and should not affect the quality of life of the patient (by causing either side effects Key words Blood flow, Intraocular pressure, or inconvenience and disruption of daily Neuroprotection, Primary open angle glaucoma, Topical medications lifestyle). The cost of the therapy, both direct and indirect, must also be taken into consideration.s Currently, typical glaucoma management Philosophy consists of lowering the lOP to a satisfactory Primary open-angle glaucoma is a complex and safe target leve1.6 To determine the success disease for which a number of risk factors have of this treatment, the patient must be followed been identified, including intraocular pressure, long-term with routine assessment of lOP, discs age, race and family history.l,2 Due to our and fields to exclude progressive damage.
    [Show full text]
  • Betaxolol Ophthalmic Solution As Alternative Treatment for Patients with Timolol Allergy: a Case Report
    Case Report Betaxolol Ophthalmic Solution as Alternative Treatment for Patients with Timolol Allergy: A Case Report Olivia Müllertz 1,*, Jette Jacobsen 2, Jacob P. Thyssen 3, Anna Horwitz 1,4 and Miriam Kolko 1,4,* 1 Department of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 2 Department of Pharmacy, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 3 Department of Dermatology and Allergy, Herlev-Gentofte Hospital, 2900 Hellerup, Denmark; [email protected] 4 Department of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, 2600 Glostrup, Denmark * Correspondence: [email protected] (O.M.); [email protected] (M.K.) Received: 24 March 2020; Accepted: 25 June 2020; Published: 30 July 2020 Abstract: Background: To establish if an allergy towards all β-blockers, as a group, should be assumed, if an allergic reaction is observed while using one specific β-blocking agent. Case presentation: The non-selective β-blocker timolol caused a severe allergic ocular reaction in a non-atopic patient with advanced primary open-angle glaucoma. Results: A patch test confirmed timolol allergy. No allergic reaction to other anti-glaucomatous topical drugs was observed, and treatment with the selective β-blocker betaxolol was successfully initiated. Conclusion: Allergy to the non-selective β-blocker timolol does not necessarily predict allergy to the selective β-blocker betaxolol, and betaxolol should therefore not be excluded as an alternative treatment. Keywords: betaxolol; timolol; β-blocker; allergy 1. Introduction Drug allergies are a class of unpredictable adverse reactions that are not related to the pharmacological effect of a drug, and can occur at subtherapeutic doses.
    [Show full text]
  • Betaxolol 0.5% Eye Drops
    Package leaflet: Information for the patient BETAXOLOL 0.5% EYE DROPS Betaxolol (as hydrochloride) Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. • Your medicine, Betaxolol 0.5% Eye Drops will be referred to as Betaxolol in this leaflet. What is in this leaflet 1. What Betaxolol is and what it is used for 2. What you need to know before you use Betaxolol 3. How to use Betaxolol 4. Possible side effects 5. How to store Betaxolol 6. Contents of the pack and other information 1. What Betaxolol is and what it is used for The active ingredient betaxolol belongs to a group of medicines called beta-blockers. Betaxolol is used to treat raised pressure of eye (intraocular pressure) which occurs in various conditions including glaucoma and ocular hypertension (high pressure in the eye) by reducing the fluid pressure in your eye(s). 2. What you need to know before you use Betaxolol Do not use Betaxolol • if you are allergic (hypersensitive) to betaxolol hydrochloride or beta-blockers or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Betaxolol Hydrochloride
    Contains Nonbinding Recommendations Draft Guidance on Betaxolol Hydrochloride This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Betaxolol hydrochloride Dosage Form; Route: Suspension/drops; ophthalmic Strength: EQ 0.25 % Base Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm in vivo Strength: EQ 0.25 % Base Subjects: Males and females with chronic open-angle glaucoma or ocular hypertension in both eyes Additional comments: Specific recommendations are provided below ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open-angle glaucoma and ocular hypertension comparing the test product versus the reference listed drug (RLD), each applied as one drop in both eyes two times daily at approximately 8:00 a.m., and 8:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open-angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • Drug Class Review Ophthalmic Beta-Adrenergic Antagonists
    Drug Class Review Ophthalmic Beta-Adrenergic Antagonists 52:40.08 Beta-Adrenergic Blocking Agents Betaxolol (Betoptic®) Carteolol (Ocupress®) Levobunolol (Betagan®) Metipranolol (Optipranolol®) Timolol (Betimol®, Timoptic®, others) Timolol/Brimonidine (Combigan®) Timolol/Dorzolamide (Cosopt®; Cosopt PF®) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 5 Table 1. Glaucoma Therapies ................................................................................................. 6 Table 2. Summary of Agents .................................................................................................. 7 Disease Overview ...................................................................................................................... 10 Table 3. Summary of Current Clinical Practice Guidelines .................................................. 11 Pharmacology ..............................................................................................................................
    [Show full text]
  • Β Blockers Timolol Betaxolol Carteolol Ocular Hypotensives: List The
    1 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol 2 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol 3 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The ‘big three’ FDA-approved PGA that dominate the American market Bimataprost (Tafluprost) An FDA-approved PGA, much less well-known than the big three (Latanaprostene bunod) A PGA ‘combo drug’ 4 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The ‘big three’ FDA-approved PGA that dominate the American market Bimataprost (Tafluprost) agonistAn FDA-approved PGA, much less well-known than the big three (Latanaprostene bunod) A PGA ‘combo drug’ 5 Q Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of tafluprost? (Tafluprost) agonistAn FDA-approved PGA, much less well-known than the big three Zioptan (and that’s all we’ll have to say about it) (Latanaprostene bunod) A PGA combo drug 6 A Ocular Hypotensives: List the common agents blockers Timolol Betaxolol Carteolol Prostaglandin analogues Latanaprost Travaprost The three FDA-approved PGA that dominate the American market Bimataprost What is the brand name of tafluprost? (Tafluprost) agonistAn
    [Show full text]
  • Drugs That May Be Used Based on Licensure Designation Page 1 of 7 Updated February 2021 by the Pennsylvania State Board of Optometry
    Drugs Which May Be Used Based on Licensure Designation Approved Drugs a.) Administration and prescription of pharmaceutical agents for therapeutic purposes. Optometrists who are certified to prescribe and administer pharmaceutical agents for therapeutic purposes under section 4.1 of the Optometric Practice and Licensure Act (63 P. S. § 244.4a), may prescribe and administer the drugs listed in subsections (c)(1) – (11) below in their practice of optometry. See also 49 Pa. Code § 23.202 for the application procedure for optometrists to administer and prescribe pharmaceutical agents for therapeutic purposes. b.) Administration and prescription of pharmaceutical agents to treat glaucoma. Optometrists who are certified to prescribe and administer pharmaceutical agents to treat glaucoma under section 4.2 of the Optometric Practice and Licensure Act (63 P.S. § 244.4b), may prescribe and administer the drugs listed in subsection (c)(12) below in their practice of optometry. See also 49 Pa. Code § 23.205 for the application procedure for optometrists to administer and prescribe pharmaceutical agents to treat glaucoma. c.) DEA registration reminder. Licensees who hold, or plan to obtain, a DEA registration are reminded to review and comply with PDMP standards. d.) Allowable pharmaceutical products. Optometrists may prescribe and administer the following pharmaceutical products or the A-rated generic therapeutically equivalent drug: (1) Topical Anesthetics (i) benoxinate (ii) lidocaine (iii) proparacaine (iv) tetracaine (2) Topical Ocular Lubricants
    [Show full text]